Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
17 May 2023
17 May 2023
Historique:
received:
24
10
2022
accepted:
28
04
2023
medline:
18
5
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
epublish
Résumé
Prognostic markers currently utilized in clinical practice for estrogen receptor-positive (ER+) and lymph node-negative (LN-) invasive breast cancer (IBC) patients include the Nottingham grading system and Oncotype Dx (ODx). However, these biomarkers are not always optimal and remain subject to inter-/intra-observer variability and high cost. In this study, we evaluated the association between computationally derived image features from H&E images and disease-free survival (DFS) in ER+ and LN- IBC. H&E images from a total of n = 321 patients with ER+ and LN- IBC from three cohorts were employed for this study (Training set: D1 (n = 116), Validation sets: D2 (n = 121) and D3 (n = 84)). A total of 343 features relating to nuclear morphology, mitotic activity, and tubule formation were computationally extracted from each slide image. A Cox regression model (IbRiS) was trained to identify significant predictors of DFS and predict a high/low-risk category using D1 and was validated on independent testing sets D2 and D3 as well as within each ODx risk category. IbRiS was significantly prognostic of DFS with a hazard ratio (HR) of 2.33 (95% confidence interval (95% CI) = 1.02-5.32, p = 0.045) on D2 and a HR of 2.94 (95% CI = 1.18-7.35, p = 0.0208) on D3. In addition, IbRiS yielded significant risk stratification within high ODx risk categories (D1 + D2: HR = 10.35, 95% CI = 1.20-89.18, p = 0.0106; D1: p = 0.0238; D2: p = 0.0389), potentially providing more granular risk stratification than offered by ODx alone.
Identifiants
pubmed: 37198173
doi: 10.1038/s41523-023-00545-y
pii: 10.1038/s41523-023-00545-y
pmc: PMC10192429
doi:
Types de publication
Journal Article
Langues
eng
Pagination
40Subventions
Organisme : NCI NIH HHS
ID : R01 CA216579
Pays : United States
Organisme : NCRR NIH HHS
ID : C06 RR012463
Pays : United States
Organisme : NIBIB NIH HHS
ID : R43 EB028736
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA239055
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA249992
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA220581
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA202752
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA208236
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA248226
Pays : United States
Organisme : BLRD VA
ID : I01 BX004121
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA257612
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA254566
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Breast. 2020 Feb;49:267-273
pubmed: 31935669
Lab Invest. 2018 Nov;98(11):1438-1448
pubmed: 29959421
Pathol Res Pract. 1990 Dec;186(6):732-6
pubmed: 1964730
Cancer. 1994 Jul 1;74(1 Suppl):381-400
pubmed: 8004612
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Nat Rev Clin Oncol. 2019 Nov;16(11):703-715
pubmed: 31399699
Breast Cancer Res Treat. 2012 Jun;133(2):553-61
pubmed: 21964579
Acta Oncol. 2000;39(1):41-5
pubmed: 10752652
J Surg Oncol. 1999 Jun;71(2):101-5
pubmed: 10389866
N Engl J Med. 2019 Jun 20;380(25):2395-2405
pubmed: 31157962
Med Image Comput Comput Assist Interv. 2013;16(Pt 3):396-403
pubmed: 24505786
Cytometry A. 2017 Jun;91(6):566-573
pubmed: 28192639
Ann Pathol. 1998 Nov;18(5):385-90
pubmed: 9864574
N Engl J Med. 2004 Dec 30;351(27):2817-26
pubmed: 15591335
J Clin Oncol. 2000 Jul;18(14):2695-701
pubmed: 10894868
Cancer Treat Res Commun. 2021;26:100306
pubmed: 33444922
Med Image Anal. 2016 Oct;33:170-175
pubmed: 27423409
Mod Pathol. 2008 Oct;21(10):1255-61
pubmed: 18360352
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Histopathology. 2002 Sep;41(3A):154-61
pubmed: 12405947
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Breast Cancer Res Treat. 2021 Jan;185(1):215-227
pubmed: 32939592
Annu Rev Biomed Eng. 2016 Jul 11;18:387-412
pubmed: 27420575
Mod Pathol. 2006 Feb;19(2):195-207
pubmed: 16341153
Tumour Biol. 2017 Mar;39(3):1010428317694550
pubmed: 28347240
Front Bioeng Biotechnol. 2019 Jun 21;7:145
pubmed: 31281813
BMC Cancer. 2018 May 30;18(1):610
pubmed: 29848291
JAMA Oncol. 2021 Mar 01;7(3):370-378
pubmed: 33475714
NPJ Breast Cancer. 2022 Oct 4;8(1):113
pubmed: 36192400
Ann Oncol. 2022 Jan;33(1):89-98
pubmed: 34756513
Int J Cancer. 2020 Feb 1;146(3):769-780
pubmed: 30977119
Breast Cancer Res Treat. 2004 Jun;85(3):219-22
pubmed: 15111759
Breast Cancer Res Treat. 1985;5(1):3-10
pubmed: 3978246
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S509-15
pubmed: 26001860
Biometrics. 1989 Mar;45(1):255-68
pubmed: 2720055
Sci Rep. 2016 Sep 07;6:32706
pubmed: 27599752
J Clin Oncol. 2008 Jul 1;26(19):3153-8
pubmed: 18490649